CliffBio
small molecule

RESTASIS MULTIDOSE

CYCLOSPORINE

Loss of exclusivityMay 2034latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameRESTASIS MULTIDOSE
Active ingredientCYCLOSPORINE
Strength0.05%
Dosage formEMULSION
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 2016
Marketing statusRX

Listed patents

PatentExpiresType
9669974May 2034product
9676525February 2034product
8561859April 2032product
8292129February 2031product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.